Sanner passes 60 million euro mark
Significant investments in Bensheim headquarters; consistent portfolio additions; cleanroom expansion in China.
With 63.7 million euro in 2016, Sanner again achieved an increase in annual sales. The company strengthened its position as a provider of high-quality plastic packaging and components for pharmaceutical, medical and healthcare products with significant domestic and international investments, the expansion of the product portfolio, as well as efficient development services for customer-specific products such as the Atmo Guard System and the newly introduced Sanner IDP-Process.
“Once again, 2016 was a very successful year for us. Compared to the previous year, we were able to increase our total turnover by 6.9%, thus exceeding the 60 million euro mark,” says Dirk Mähr, Managing Director of Sanner. “This continuous growth, as well as the numerous developments and investments show that we are well prepared for the future", says Ralf Tiemann, Managing Director Sanner Kunshan China.
Comprehensive investments and portfolio expansions
Investments included an exchange of most machines for Sanner products in Bensheim, Germany. “The increase in automation and the acquisition of new production machines contribute to an increase in capacity and efficiency,” says Mähr. In the coming years, Sanner will consistently expand its portfolio for capsules and desiccant packaging.
The company has also strengthened the range of services and developments of customer-specific products with the Sanner Atmo Guard System and the IDPProcess , which was recently introduced at Pharmapack Europe. The IDPProcess meets the growing need for customized, holistic packaging concepts for pharmaceuticals and medical devices. Customers receive individual packaging solutions with a design that not only meets the highest requirements, but which is also suited for large-scale serial production, while fulfilling all technical and regulatory demands.
Expansion of cleanroom capacities in China
The expansion of the cleanroom capacities in Kunshan, China, focused on efficiency and product safety. Since February 2017, 200 additional square meters of production space are available at the site. However, Sanner does not rest on its laurels: “The past years’ successful business results and our excellent future prospects in Asia will require continuous capacity expansions over the coming years,” says Ralf Tiemann. Upon completion of the second construction phase at the end of the first half-year, the company will be able to produce in 2,700 square meters of cleanroom space.
Well-positioned for further growth
A great deal has also happened at the production site in Hungary: on one hand, new employees could be recruited to strengthen the team. On the other hand, the sites in Bensheim and Budapest are cooperating more closely to establish a broader platform for future growth projects in Europe. "With these numerous portfolio and capacity expansions, we are sustainably investing in the future of our production sites", Dirk Mähr summarizes. "This way, Sanner is well positioned for further growth."
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance